NEOMED’s objectives for BIO:
• Identify licensing partners/financial partners for NEOMED’s therapeutic pipeline
• Identify new in-licensing opportunities
• Showcase NEOMED Innovation Center’s expansion project
Montreal, QC, Canada May 31st, 2018 – The NEOMED Institute announced its participation at the 25th BIO International Convention, from June 4th to the 7th, in Boston.
“BIO continues to be a tremendous partnering event for NEOMED. It provides for the opportunity to carry on existing conversations and start new ones with potential partners interested in our rich portfolio of assets that we are looking to license. I look forward to the many 1-on-1 meetings we have scheduled” rejoiced Daniel Böck, NEOMED Institute’s Vice President of Business Development.
“NEOMED is actively seeking promising drug discovery projects based on innovative therapeutic targets. With more than 16,000 attendees, BIO 2018 is an important event to explore new potential in-licensing opportunities coming from academia” added Patricia Escoffier, NEOMED Institute’s Scientific Affairs Director.
During the Convention, Donald Olds, NEOMED Institute’s President and CEO, will also be a panelist at the National Panel on Accelerators and Incubators, organized by BIOTECanada on Tuesday June 5th. “I am very excited to have been invited by BIOTECanada to participate in their national panel on accelerators and incubators. We are very proud of the success we have had over our first 5 years creating a leading Canadian life sciences ecosystem with over 30 companies and 350 employees and continuing our work to advance great Canadian science from our universities and research centers towards successful commercialization” declared Donald Olds.
BIO is also an anticipated event for the “NEOMED Innovation Center, division of the NEOMED Institute, which is currently seeking new tenants to be part of the 50,000 ft2expansion of Labs and offices and join the already established ecosystem of 20 companies and 300 scientists, at our Montreal’s site” concluded Pierre-Yves Desbiens, Chief Operating Officer of the Institute.
About the NEOMED Institute (NEOMED)
The NEOMED Institute is a successful and innovative Canadian not-for-profit R&D organization with a single mission: to enable and accelerate the commercialization of Canadian life science discoveries. To accomplish this mission, NEOMED Institute operates two complementary and integrated divisions:
The NEOMED Institute is funded by pharmaceutical partners, the Ministère de l’Économie, de la Science et de l’Innovation du Québec, and the Networks of Centres of Excellence (NCE) of Canada as well as the revenue generated from the out-licensing/sale of their pipeline projects and the operation of their facilities. For more information, please visit www.neomed.ca.
NEOMED Media Enquiries:
Tel.: 514-367-1212 ext. 218